Perrigo (NYSE:PRGO) Announces Earnings Results

Posted by Francis Steltz on Aug 5th, 2026

Perrigo (NYSE:PRGO – Get Free Report) issued its quarterly earnings data on Wednesday. The company reported $0.50 EPS for the quarter, beating the consensus estimate of $0.34 by $0.16, FiscalAI reports. The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. Perrigo had a positive return on equity of 9.96% and a negative net margin of 43.50%.Perrigo’s quarterly revenue was down 3.1% compared to the same quarter last year. During the same period last year, the company earned ($0.06) earnings per share. Perrigo updated its FY 2026 guidance to 2.250-2.550 EPS.

Here are the key takeaways from Perrigo’s conference call:

Market share gains continued despite weak categories: U.S. store-brand OTC volumes grew 1.5% and gained 50 basis points of share, while European key brands grew 3.3% and also gained 50 basis points.
Perrigo reaffirmed its full-year 2026 outlook, citing improving category trends, innovation and distribution gains, operational savings, and lower interest expense following debt repayment.
Q2 core net sales fell 3.1% and core adjusted EPS declined to $0.46, while core adjusted gross margin dropped 250 basis points to 37%. Results benefited from approximately $10 million in tariff recoveries and a $6 million CEO-transition benefit, limiting the significance of the earnings beat.
The company applied most of the $359 million Dermacosmetics sale proceeds to debt reduction, lowering its revolving credit balance, while its operational enhancement program remains on track to generate $80 million–$100 million in savings by 2027.
Strategic reviews of the infant formula and oral care businesses are progressing, with Perrigo considering optimization, partnerships, or divestitures; management said improved infant-formula performance provides greater optionality but does not alter the review process.

Perrigo Price Performance

Shares of NYSE:PRGO traded up $2.77 during midday trading on Wednesday, hitting $13.54. The company had a trading volume of 5,841,156 shares, compared to its average volume of 3,200,532. Perrigo has a twelve month low of $9.23 and a twelve month high of $24.60. The stock has a market cap of $1.87 billion, a price-to-earnings ratio of -1.03, a price-to-earnings-growth ratio of 1.28 and a beta of 0.51. The company has a debt-to-equity ratio of 1.45, a current ratio of 2.72 and a quick ratio of 1.59. The business’s 50-day simple moving average is $10.52 and its 200-day simple moving average is $11.56.

Perrigo Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Friday, August 28th will be issued a $0.29 dividend. This represents a $1.16 annualized dividend and a dividend yield of 8.6%. The ex-dividend date of this dividend is Friday, August 28th. Perrigo’s dividend payout ratio (DPR) is currently -8.85%.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on PRGO. Weiss Ratings raised shares of Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 21st. Zacks Research raised shares of Perrigo from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. One investment analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $19.33.

Read Our Latest Analysis on Perrigo

Institutional Trading of Perrigo

A number of hedge funds and other institutional investors have recently modified their holdings of PRGO. Brooklyn Investment Group acquired a new position in shares of Perrigo during the 4th quarter valued at about $268,000. United Services Automobile Association acquired a new position in Perrigo in the 1st quarter valued at about $250,000. Meeder Advisory Services Inc. acquired a new position in Perrigo in the 4th quarter valued at about $238,000. M&T Bank Corp increased its holdings in shares of Perrigo by 20.5% during the 2nd quarter. M&T Bank Corp now owns 7,956 shares of the company’s stock worth $213,000 after buying an additional 1,354 shares during the last quarter. Finally, Aristides Capital LLC purchased a new stake in shares of Perrigo during the 4th quarter valued at approximately $212,000. 95.91% of the stock is owned by institutional investors and hedge funds.

More Perrigo News

Here are the key news stories impacting Perrigo this week:

Positive Sentiment: Q2 earnings beat estimates: Perrigo reported adjusted earnings of $0.50 per share, above the $0.31-$0.34 analyst consensus and up from a loss of $0.06 per share in the year-ago quarter. Revenue of approximately $1.02 billion also topped the $1.01 billion estimate. Perrigo Surpasses Q2 Earnings and Revenue Estimates
Positive Sentiment: Profitability improved substantially: Net income was $74.5 million versus a net loss of $8.4 million a year earlier. Reported diluted earnings from continuing operations were $0.63 per share, compared with break-even results in the prior-year period. Perrigo Reports Second Quarter 2026 Financial Results
Positive Sentiment: Full-year guidance was maintained and earnings expectations increased: Perrigo provided FY 2026 EPS guidance of $2.25-$2.55, above the roughly $2.11 consensus estimate. Management expects sequentially stronger performance in the second half and cited market-share gains in U.S. store-brand over-the-counter products and key European brands. Perrigo Q2 Key Metrics
Neutral Sentiment: Perrigo completed its Dermacosmetics divestiture and continues strategic reviews of its Infant Formula and Oral Care businesses, actions that could streamline the portfolio but also introduce execution uncertainty.
Negative Sentiment: Sales remained under pressure: Q2 net sales declined 3.2% year over year to $1.02 billion, while core organic sales fell 3.5%. Management cited category softness and macroeconomic headwinds, although Infant Formula sales rose 23.1% primarily because of shipment timing. Perrigo Q2 Net Sales Report

Perrigo Company Profile

(Get Free Report)

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.